Advisors Capital Management LLC Acquires 2,046 Shares of Boston Scientific Corporation $BSX

Advisors Capital Management LLC increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 46.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,446 shares of the medical equipment provider’s stock after purchasing an additional 2,046 shares during the period. Advisors Capital Management LLC’s holdings in Boston Scientific were worth $692,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares in the last quarter. Geode Capital Management LLC raised its holdings in Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after purchasing an additional 622,602 shares in the last quarter. Invesco Ltd. lifted its position in shares of Boston Scientific by 5.3% during the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock valued at $1,677,124,000 after buying an additional 834,274 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after buying an additional 1,383,524 shares in the last quarter. Finally, Amundi grew its position in shares of Boston Scientific by 2.6% in the 1st quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock worth $1,212,408,000 after buying an additional 311,034 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 175,782 shares of company stock worth $17,742,314 over the last 90 days. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Down 2.1%

Shares of NYSE BSX opened at $102.73 on Friday. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company’s 50-day simple moving average is $99.72 and its 200-day simple moving average is $102.56. The firm has a market cap of $152.30 billion, a price-to-earnings ratio of 54.94, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the topic of several analyst reports. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Raymond James Financial boosted their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Canaccord Genuity Group reiterated a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research note on Thursday, October 23rd. UBS Group raised their price target on Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Wells Fargo & Company upped their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and an average price target of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.